Ximluci Europska Unija - hrvatski - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Movymia Europska Unija - hrvatski - EMA (European Medicines Agency)

movymia

stada arzneimittel ag - teriparatid - osteoporoza - homeostaza kalcija - movymia je indicirana kod odraslih osoba. liječenje osteoporoze u žena u postmenopauzi i muškaraca pri povećanom riziku od loma. u žena u postmenopauzi pokazano je značajno smanjenje učestalosti prijeloma kralješnjaka i ne-kralješaka, ali ne i fraktura kuka. liječenje osteoporoze, povezan sa stalnim sistemsku terapiju s glukokortikoidi, kod žena i muškaraca pod povećanim rizikom prijeloma.

Oyavas Europska Unija - hrvatski - EMA (European Medicines Agency)

oyavas

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

SORAFENIB STADA 200 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sorafenib stada 200 mg/1 tableta film tableta

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - sorafenib - film tableta - 200 mg/1 tableta - 1 film tableta sadrži: 200 mg sorafeniba u obliku sorafenib tosilata

SORAFENIB STADA 400 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sorafenib stada 400 mg/1 tableta film tableta

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - sorafenib - film tableta - 400 mg/1 tableta - 1 film tableta sadrži: 400 mg sorafeniba u obliku sorafenib tosilata

AZACITIDIN STADA 100 mg/1 bočica prašak za suspenziju za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

azacitidin stada 100 mg/1 bočica prašak za suspenziju za injekciju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - azacitidin - prašak za suspenziju za injekciju - 100 mg/1 bočica - 1 bočica sa praškom za suspenziju za injekciju sadrži: 100 mg azacitidina (nakon rekonstitucije svaki ml suspenzije sadrži 25 mg azacitidina)

Tramal 100 mg/ml oralne kapi, otopina Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

tramal 100 mg/ml oralne kapi, otopina

stada d.o.o., hercegovačka 14, zagreb, hrvatska - tramadolklorid - oralne kapi, otopina - 100 mg/ml - urbroj: 20 oralnih kapi (što odgovara 0,5 ml otopine) u bočici s nastavkom za kapanje sadrži 50 mg tramadolklorida; 4 pritiska na pumpicu (što odgovara 0,5 ml otopine) u bočici s odmjernom pumpicom sadrži 50 mg tramadolklorida

Vilbaco 50 mg/850 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

vilbaco 50 mg/850 mg filmom obložene tablete

stada d.o.o., hercegovačka 14, zagreb, hrvatska - vildagliptin metforminklorid - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 50 mg vildagliptina i 850 mg metforminklorida (što odgovara 660 mg metformina)

Liglinra 5 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

liglinra 5 mg filmom obložene tablete

stada d.o.o., hercegovačka 14, zagreb, hrvatska - линаглиптин - filmom obložena tableta - urbroj: jedna tableta sadrži 5 mg linagliptina

Ibufix Forte 400 mg/10 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ibufix forte 400 mg/10 mg filmom obložene tablete

stada d.o.o., hercegovačka 14, zagreb, hrvatska - ibuprofen fenilefrinklorid - filmom obložena tableta - 400 mg + 10 mg - urbroj: jedna filmom obložena tableta sadrži 400 mg ibuprofena i 10 mg fenilefrinklorida